Cerebrolysin

Cerebrolysin is a manufactured drug, not a single peptide: an enzymatically digested mixture of low-molecular-weight peptide fragments and free amino acids from purified porcine brain tissue. It is approved as a prescription drug in Austria, Russia, China and other countries, but never by the FDA or EMA. It has more Western, randomized, double-blind, placebo-controlled human trials than most compounds this site covers, and the results are genuinely mixed: positive in a stroke motor-recovery trial and an Alzheimer’s meta-analysis, neutral in a subarachnoid hemorrhage trial.

Ask about Cerebrolysin

Research snapshot

Peptide categoryManufactured drug: enzymatically digested mixture of low-molecular-weight peptide fragments and free amino acids from purified porcine brain tissue
Primary research interestStroke motor recovery, Alzheimer’s cognition, and acute brain injury (subarachnoid hemorrhage) as an adjunct treatment
Highest available evidenceMultiple published randomized, double-blind, placebo-controlled human clinical trials and a meta-analysis
Human research availableYes, extensively: but with genuinely mixed results across indications
Development statusLong-marketed drug (not a novel research compound); results mixed across trial populations
Regulatory statusApproved as a prescription drug in Austria, Russia, China and other jurisdictions; never approved by the FDA or EMA

Technical identity

Primary nameCerebrolysin
Alternative namesCerebrolysine; FPF 1070; “porcine brain peptide” (community name)
Peptide sequenceNot applicable: a complex, undefined mixture of low-molecular-weight peptide fragments (~25%) and free amino acids (~75%), not a single defined sequence
Amino-acid lengthNot applicable (heterogeneous mixture)
Molecular formulaNot applicable: mixture, not a single molecule
Molecular weightNot applicable: mixture of low-molecular-weight fragments and free amino acids
CAS Registry NumberNot applicable to the mixture as a whole; individual components each have their own identifiers
PubChem CIDNot applicable: mixture, not a single compound
UNIINot established
DrugBank IDNot established
Chemical modificationsStandardized enzymatic breakdown (digestion) of purified porcine brain proteins
Peptide classManufactured neuropeptide/amino-acid mixture drug (pleiotropic, no single isolated active component)
Primary biological targetNot conclusively established: proposed neurotrophic-factor-like, anti-excitotoxic and anti-inflammatory activity, not pinned to one component
Developer or originatorEVER Neuro Pharma (Austria)
Development statusCommercialized prescription drug in select countries; never approved by FDA or EMA

What it is

Cerebrolysin is a manufactured drug, not a single defined peptide. It is produced by standardized enzymatic breakdown of purified porcine brain proteins, yielding a mixture of low-molecular-weight peptide fragments (about 25% of the preparation by the manufacturer’s account) and free amino acids (about 75%). It is manufactured by EVER Neuro Pharma (Austria) and is approved as a prescription drug in Austria, Russia, China and several other countries as a “nootropic” and neuroprotective agent. It has never been approved by the FDA or the EMA, and it has no United States prescribing information.

Because it is a complex biological mixture rather than a single molecule, its mechanism is described as pleiotropic: proposed effects include neurotrophic-factor-like activity, reduced excitotoxicity, and anti-inflammatory action, none of which has been pinned to a single active component in the sources reviewed for this entry.

Potential benefits and research applications

Motor recovery after stroke, the strongest positive finding

The CARS trial, a multicenter randomized double-blind placebo-controlled study, reported a large effect favoring Cerebrolysin on upper-extremity motor function at day 90 in stroke patients who also received standardized rehabilitation. The authors themselves described it as exploratory, with a relatively small sample, and called for confirmation in a larger trial.

Evidence: has been shown in one randomized, double-blind, placebo-controlled human trial (Tier 1, published human clinical evidence); not yet confirmed in a larger, independent trial.

Cognitive benefit in mild-to-moderate Alzheimer’s disease

A 2015 meta-analysis pooling six randomized, double-blind, placebo-controlled trials reported a statistically significant benefit on cognitive function at 4 weeks and on global clinical change at both 4 weeks and 6 months, with a safety profile comparable to placebo.

Evidence: has been shown across multiple randomized, placebo-controlled human trials (Tier 1, published human clinical evidence, pooled analysis); durability beyond 6 months and comparison against current standard-of-care Alzheimer’s treatments were not established in the sources reviewed.

Recovery after acute brain injury more broadly, an inconsistent picture

A separate randomized, double-blind, placebo-controlled pilot trial in aneurysmal subarachnoid hemorrhage, using the same 30 mL/day dose, found no significant difference between Cerebrolysin and placebo on six-month functional outcome, cognitive performance, or delayed cerebral ischemia.

Evidence: has not been established for acute brain injury generally; a randomized, placebo-controlled human trial (Tier 1) in this specific population was neutral, showing that a positive result in one acute-injury setting (stroke) does not generalise automatically to another (subarachnoid hemorrhage).

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Stroke motor recovery (CARS trial)Daily IV infusion30 mL/dayOnce daily21 days, starting 24-72 hours post-strokePublished human clinical trial (randomized, double-blind, placebo-controlled)
Aneurysmal subarachnoid hemorrhage (Woo 2020)IV30 mL/dayOnce daily14 daysPublished human clinical trial (randomized, double-blind, placebo-controlled; neutral result)
Mild-to-moderate Alzheimer’s disease (Gauthier 2015 meta-analysis)IV infusion30 mL/dayOnce dailyVaries by pooled trial; outcomes at 4 weeks and 6 monthsPublished human meta-analysis (6 pooled randomized, double-blind, placebo-controlled trials)
Cognitive/nootropic use, general (community)Intramuscular or subcutaneousCommonly reported as 1 to 5 mL per dose (from 5 mL or 10 mL ampoules), a fraction of the 30 mL/day IV trial doseOnce daily, often cycled10 to 20 day coursesCommunity / vendor reported

The human trial record

Cerebrolysin has more Western, randomized, double-blind, placebo-controlled human trials behind it than most compounds on this site, and the results across them do not point in one direction.

The Cerebrolysin and Recovery After Stroke (CARS) trial, a multicenter randomized double-blind placebo-controlled study, gave stroke patients 30 mL/day of Cerebrolysin by daily infusion for 21 days, starting 24 to 72 hours after stroke onset, alongside standardized rehabilitation. It reported a large effect favoring Cerebrolysin on upper-extremity motor function (Action Research Arm Test) at day 90, and the authors themselves described the study as exploratory with a relatively small sample size, calling for confirmation in a larger trial.

A separate randomized, double-blind, placebo-controlled pilot trial in 50 patients with aneurysmal subarachnoid hemorrhage, using the same 30 mL/day dose for 14 days, found no significant difference between Cerebrolysin and placebo on six-month functional outcome, cognitive performance, or the rate of delayed cerebral ischemia. It was safe and well tolerated, but neutral on efficacy.

A 2015 meta-analysis pooling six randomized, double-blind, placebo-controlled trials of 30 mL/day of Cerebrolysin in mild-to-moderate Alzheimer’s disease reported a statistically significant benefit on cognitive function at 4 weeks and on global clinical change at both 4 weeks and 6 months, with a safety profile comparable to placebo.

A completed Phase 2 trial in Down syndrome and ongoing motor-recovery trials after stroke round out a body of research that keeps returning to this compound for different indications, without any single result being decisive.

What is not known

Which component of this multi-molecule mixture, if any, is responsible for the effects reported in some trials and absent in others. A defined single active ingredient has not been isolated in the sources reviewed for this entry.

Why the subarachnoid hemorrhage trial and the stroke motor-recovery trial reached different conclusions at the same 30 mL/day dose. Population, timing after injury and outcome measure all differed between them, and no synthesis reconciling the results was located.

Whether the results generalise to indications outside stroke, Alzheimer’s disease and Down syndrome, the three areas with published randomized trials.

Frequently asked questions

What is Cerebrolysin?

It is a manufactured mixture of peptide fragments and free amino acids from enzymatically digested porcine brain tissue, not a single defined peptide. It is approved as a prescription drug in several countries but not by the FDA or EMA.

How does Cerebrolysin work?

Its mechanism is described as pleiotropic, with proposed neurotrophic-factor-like, anti-excitotoxic and anti-inflammatory effects. No single active component responsible for these effects has been isolated in the sources reviewed for this entry.

What dosage has been studied in humans?

Published trials used 30 mL per day by daily infusion, for 14 to 21 days depending on the trial, under medical supervision.

What dosage commonly circulates online?

Self-use material typically describes 1 to 5 mL by intramuscular or subcutaneous injection, once daily, in 10- to 20-day courses. This is a small fraction of the 30 mL/day IV dose used in the published trials, and by a different route.

Has Cerebrolysin been studied in humans?

Yes, extensively, including randomized, double-blind, placebo-controlled trials in stroke, subarachnoid hemorrhage and Alzheimer’s disease, plus a completed Phase 2 trial in Down syndrome.

Is Cerebrolysin approved for use?

It is approved as a prescription drug in Austria, Russia, China and several other countries. It has never been approved by the FDA or EMA and has no US prescribing information.

What routes of administration are reported?

Published trials used daily IV infusion. Self-administered use is generally by intramuscular or subcutaneous injection.

Does Cerebrolysin work for every condition it is used for?

No. The trial record is mixed: positive results in stroke motor recovery and Alzheimer’s cognition, but a neutral result in a subarachnoid hemorrhage trial at the same dose.

What side effects have been reported?

The trials reviewed for this entry generally reported a safety profile comparable to placebo, with the subarachnoid hemorrhage pilot specifically describing it as safe and well tolerated.

What remains unknown about Cerebrolysin?

Which component of this multi-molecule mixture drives its effects, why trials in different acute brain injury populations reached different conclusions at the same dose, and whether its benefits generalise beyond stroke, Alzheimer’s disease and Down syndrome.

Bottom line

Cerebrolysin is unusual among the compounds on this site: it has a substantial body of Western, randomized, double-blind, placebo-controlled human trials, not just animal or observational data. But it is a complex, undefined mixture rather than a single active molecule, and its trial results genuinely disagree with each other across indications, positive in stroke recovery and Alzheimer’s cognition, neutral in subarachnoid hemorrhage. It remains unapproved by the FDA and EMA, and the doses used in self-administered protocols are a small fraction of what any cited trial actually tested.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Cognitive/nootropic use, generalIntramuscular or subcutaneous1 to 5 mL per dose (from 5 mL or 10 mL ampoules)Once daily, often cycled in courses10 to 20 day courses

Cerebrolysin is manufactured and sold as 1, 5, 10, 20 and 30 mL ampoules for clinical IM or IV use, and circulating self-use material generally describes 1 to 5 mL by intramuscular or subcutaneous injection, once daily. The published trials used 30 mL per day by IV infusion, which would take 6 to 30 of those same ampoules to match. A self-administered intramuscular dose in the low single-digit milliliters is a fraction of the volume, and by a different route, than what any cited trial actually tested.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Research area: Neuro and cognitive.

Share thisFacebookXEmail